##semicolon##
genetic predisposition, immunoinflammatory, comorbid diseases, autoimmune disease.##submission.citations##
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388 (10055):2023-38.
Gerlag DM, Raza K, van Baarsen LGM et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012; 71:638–41.
Mankia K, Emery P. Preclinical rheumatoid arthritis. Progress toward prevention. Arthritis Rheumatol 2016; 68:779-88.
Boeters DM, Raza K, Vander Helmvan Mil AHM. Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art. RMD Open 2017;3(2):e000479.
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389(10086):2328-37.
Catrina AI, Svensson CI, Malmstr öm V, et al. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Immunol 2017;13(2):79-86.
Leandro M. B cells and rheumatoid factors in autoimmunity. Int J Rheum Dis 2015; 18:379-81.
Dörner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther 2009; 11:247.
Cantagrel A, Degboe Y. New autoantibodies associated with rheumatoid arthritis re co gnize posttranslationally modified self-protein. Joint Bone Spine 2016;83: 11-7.
Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569-81.
Aletaha D, Bl üml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open 2016;2(1):e000009.
Willemze A, Trouw LA, Toes RE, Huizinga TWJ. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012; 8:114-152.
Jilani AA, Mackworth-Young CG. The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systemic literature review and meta-analysis. Int J Rheumatol 2015; 2015:8.
Kuller LH, Mackey RH, Walitt BT, et al. Determinants of mortality among postmenopausal women in the Women`s health initiative who report rheumatoid arthritis. Arthritis Rheum 2014; 66:497-507.
Humphreys J, van Nies JAB, Chupping J, et al. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohort. Arthritis Res Ther 2014; 16:483.
Sakkas LI, Bogdanos DP, Katsiari C, Platsoucas CD. Anti-citrullinated peptide as autoantigen in rheumatoid arthritis – relevance to treatment. Autoimmune Rev 2014; 13:1114-20.
Malmstrom V, Cartina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Rheumatol 2017; 13(2): 79-86.
Yarwood A, Huizinga TWJ, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology (Oxford) 2016;55(2):199-209.
Ma WT, Chang C, Gershwin ME, Lian ZX. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. J Autoimmun 2017; 83:95-112.
Seeling M, Bruckner C, Nimmerjahn F. Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? Nat Rev Rheumatol 2017;13(10):621-30.
Corsiero E, Pratesi F, Prediletto E, et al. NETosis as source of autoantigens in rheumatoid arthritis. Front Immunol 2016; 7:485.
Harre U, Georgess D, Bang H et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012;122: 1791–802.
Krishnamurthy A, Joshua V, Haj Hensvold A et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritisassociated autoantibody-mediated bone loss. Ann Rheum Dis 2016; 75:721–9.
Wigerblad G, Bas DB, Fernades-Cerqueira C et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokinedependent mechanism. Ann Rheum Dis 2016; 75:730–8.
Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015; 11:415-29
Pfeifle R, Rothe T, Ipseiz N et al. Regulation of autoantibody activity by the IL23-TH17 axis determines the onset of autoimmune disease. Nat Immunol 2017; 18:104–13.
Насонов Е.Л. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология 2017;55:68-86.
Deane KD, Demoruelle MK, Kelmenson LB, et al. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol 2017; 31:3-18.
Joshua V, Chatzidionisyou K, Catrina AI. Role of the lung in individuals at risk of rheumatoid arthritis.Best Pract Res Clin Rheumatol 2017;3131-41.
Cheng Z, Meade J, Mankia K, et al. Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis. Best Pract Res Clin Rheumatol 2017; 31:19-30.
Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205–13.
Scally SW, Petersen J, Law SC, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013;210: 2569–82.
Yarwood A, Huizinga TWJ, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology (Oxford) 2016; 55:199–209.
Chang HH, Liu GY, Dwivedi N et al. A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22. JCI Insight 2016; 1(17):e90045.
Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet 2017;389(10086):2338-48.
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389(10086):2328-37.
Насонов Е.Л. (ред). Генно-инженерные биологические препараты в лече нии ревматоидного артрита. Москва, ИМА-ПРЕСС, 2013.
Smolen JS, Aletaha D, Bijsma JWJ et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69:631-7.
Cope AP. Emerging therapies for pre-RA. Best Pract Res Clin Rheumatol 2017; 31(1):99-111.
McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017; 389:2328-37.
McInnes IB, Buckley CD, Isaaks JD. Cytokines in rheumatoid arthritis – shaping the immunological landscape. Nat Rev Rheumatol 2016; 12:63-8.
Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity 2017 21; 46:183-96.
Dekkers JS, Schoones JW, Huizinga TW, et al. Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis. Ann Rheum Dis 2017;76: 458-67.
Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol 2015; 27:55-62.
Kalliolias GD, Ivashkiv LB. TNF biology, pathogenetic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 2016; 12:49-62
Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014; 10:612-27.
Насонов Е.Л. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология 2015; 53: 421-33.
Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Molec Med 2016; 22:230-41.
Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated disease. Annu Rev Med 2016:67:337-53.
McInnes IB, Porter D, Siebert S. Choosing new targets for rheumatoid arthritis therapeutics: too interesting to Fail? Arthritis Rheum 2017; 69: 1131-4.
Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol 2016; 12: 37-48.
Avci AB, Feist E, Burmester GR. Targeting GM-CSF in rheumatoid arthritis. Clin Exp Rheumatol 2016;34(4 Suppl 98):39–44.
Huizinga TW, Batalov A, Stoilov R, et al. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther 2017; 9:53.
Jutley GS, Latif ZP, Raza K. Symptoms in individuals at risk of rheumatoid arthritis.Best Pract Res Clin Rheumatol 2017;31:59-70.
Van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56:433–40.
van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJJ. EULAR definition of arthralgia suspicious for progression Насонов Е.Л. (ред.). Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012: 55–93.